ホーム › 急性リンパ性白血病 › ワシントン › Seattle
Seattle、WAにおける急性リンパ性白血病の臨床試験
Seattleとその周辺地域（約30マイル以内）の拠点で、急性リンパ性白血病に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
被験者募集中
- Seattle Children's, University of Washington, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- 他1件
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
被験者募集中第2相
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Seattle Children's Hospital, Seattle
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
被験者募集中観察研究
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Multicenter HomeVENT: Home Values and Experiences Navigation Track
被験者募集中健康なボランティア歓迎
- Seattle Childrens Hospital, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
被験者募集中第1/2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
被験者募集中第1/2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
被験者募集中第2相健康なボランティア歓迎
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
被験者募集中第1相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
被験者募集中観察研究
- Seattle Children's Hospital, Seattle
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
被験者募集中第3相
- Ascentage Investigative Site #1806, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
被験者募集中第1相
- Fred Hutchinson Cancer Research Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
被験者募集中第1相
- Seattle Children's Hospital, Seattle
他の都市における急性リンパ性白血病の試験
- Houston, TX28件の研究
- New York City, NY24件の研究
- Baldwin Park, CA21件の研究
- Chicago, IL19件の研究
- Atlanta, GA19件の研究
- Philadelphia, PA16件の研究
- Memphis, TN16件の研究
- Washington, DC16件の研究
- Boston, MA15件の研究
- Los Angeles, CA14件の研究
- Durham, NC13件の研究
- Mountain View, CA13件の研究
Seattleにおける他の研究
- 非小細胞肺癌53件の研究
- がん（全種類）49件の研究
- 前立腺がん42件の研究
- 急性骨髄性白血病40件の研究
- 乳がん39件の研究
- 転移性癌39件の研究
- 大腸癌34件の研究
- 肺がん33件の研究
- 卵巣がん30件の研究
- 多発性骨髄腫22件の研究
- 骨髄異形成症候群21件の研究
- 膀胱癌21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。